Literature DB >> 2845766

Receptors for calcium antagonists.

A Schwartz1, E McKenna, P L Vaghy.   

Abstract

Calcium antagonists have been divided into 3 different subclasses represented by nifedipine, verapamil and diltiazem. These drugs have different pharmacologic effects and are not interchangeable. Previous studies suggested that all calcium antagonists bind to a 170 kd polypeptide (now called the alpha 2 subunit of the voltage-dependent calcium channel). The apparent molecular weight of this polypeptide characteristically decreased from 170 to 140 kd upon disulfide reduction as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Recent studies demonstrated that calcium antagonists bind to a previously unrecognized 165 kd polypeptide (alpha 1 subunit) that does not change its electrophoretic mobility on disulfide reduction. Because of their similar molecular weights, the 2 polypeptides may overlap each other on polyacrylamide gels. The primary structure of both polypeptides clearly shows, however, that they are different from each other and only the alpha 1 subunit has the features expected of an ion channel.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2845766     DOI: 10.1016/0002-9149(88)90024-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  The use of calcium blockers to study biochemical behaviour of Saccharomyces cerevisiae cells.

Authors:  R de Souza Pereira
Journal:  Mol Cell Biochem       Date:  2001-12       Impact factor: 3.396

2.  Different negative inotropic activity of Ca2(+)-antagonists in human myocardial tissue.

Authors:  R H Schwinger; M Böhm; E Erdmann
Journal:  Klin Wochenschr       Date:  1990-08-17

Review 3.  Strategies for managing perioperative hypertension.

Authors:  Ronak G Desai; Muhammad Muntazar; Michael E Goldberg
Journal:  Curr Hypertens Rep       Date:  2009-06       Impact factor: 5.369

Review 4.  How do calcium antagonists differ in clinical practice?

Authors:  R Ferrari; F Cucchini; R Bolognesi; T Bachetti; A Boraso; P Bernocchi; G Gaia; O Visioli
Journal:  Cardiovasc Drugs Ther       Date:  1994-08       Impact factor: 3.727

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.